When did Nuvectis Pharma, Inc. report Q4 2024 earnings?

Nuvectis Pharma, Inc. (NVCT) reported Q4 2024 earnings on February 25, 2025 before market open.

What were Nuvectis Pharma, Inc.'s Q4 2024 revenue and EPS?

Nuvectis Pharma, Inc. reported eps of $-0.36 for Q4 2024.

EPS missed the consensus estimate of $-0.28 by $0.08.

You can read the 10-K periodic report (0001558370-25-001496) directly on SEC EDGAR. The filing index links above go to sec.gov.

Reported February 25, 2025 · Before market open

EPS-$0.36Miss by $0.08

EPS estimate-$0.28

Aug 4, 2026 (In 5 days)

EPS estimate-$0.25

Q4 2024

Operating income-$6.4M+6.1%

Net income-$6.2M+5.6%

EPS (diluted)-$0.36+12.2%

Cash & equivalents$18.5M-3.1%

Total equity$9.7M-20.4%

Total assets$18.6M-3.0%

Operating cash flow-$2.5M+36.0%

as of 12/31/24

Market cap$104.53M-28.0%

Return on equity-173.4%+5.2pp

Current ratio2.1×-0.7×

Q4 2024-$0.36Miss by $0.08

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

When did Nuvectis Pharma, Inc. report Q4 2024 earnings?: Nuvectis Pharma, Inc. (NVCT) reported Q4 2024 earnings on February 25, 2025 before market open.
What were Nuvectis Pharma, Inc.'s Q4 2024 revenue and EPS?: Nuvectis Pharma, Inc. reported eps of $-0.36 for Q4 2024.
Did Nuvectis Pharma, Inc. beat estimates in Q4 2024?: EPS missed the consensus estimate of $-0.28 by $0.08.
Where can I find Nuvectis Pharma, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001558370-25-001496) directly on SEC EDGAR. The filing index links above go to sec.gov.